Search or ask a question

Which drug is not used in tuberculosis?

Click chemistry

Mycobacterium tuberculosis

Answers from top 4 papers

PDF

Open Access

More filters

Papers (4)	Insight
Open access•Journal Article•DOI Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis Kelly E. Dooley, Carole D. Mitnick, Mary Ann DeGroote, Ekwaro A. Obuku, Vera Belitsky, Carol Dukes Hamilton, Mamodikoe Makhene, Sarita Shah, James C.M. Brust, Nadza Durakovic, Eric L. Nuermberger - Show less +10 more 15 Aug 2012-Clinical Infectious Diseases 65 Citations	Results suggest that optimizing the dosing of pyrazinamide, the injectables, and isoniazid for drug-resistant tuberculosis is a high priority.
Journal Article•DOI Tuberculosis. Part I. Lawrence J. McDermott, Jeffrey Glassroth, Jay B. Mehta, Asim K. Dutt, Asim K. Dutt - Show less +4 more 01 Mar 1997-Dm Disease-a-month 9 Citations	Two-drug up to seven-drug therapy may be indicated for a case of tuberculosis, depending on evidence of the presence of multiple drug resistance.
Journal Article•DOI An Overview of Phytotherapeutic Approaches for the Treatment of Tuberculosis Dushyant Sharma, Jaya Parkash Yadav - Show less +1 more 31 Dec 2016-Mini-reviews in Medicinal Chemistry 18 Citations	which have antimicrobial activity; thus may be useful in control of tuberculosis.
Open access•Journal Article•DOI Increase of leishmanicidal and tubercular activities using steroids linked to aminoquinoline Luciana M.R. Antinarelli, Arturene Maria Lima Carmo, Fernando Rogério Pavan, Clarice Queico Fukimura Leite, Adilson Davida da Silva, Elaine Soares Coimbra, Deepak B. Salunke - Show less +6 more 02 May 2012 24 Citations	This result is comparable to drugs commonly used in tuberculosis treatment.

My columns

Related Questions

How effective is TB47 in treating mycobacterium infections compared to other available drugs?5 answersTB47, a pyrazolo[1,5-a]pyridine-3-carboxamide, shows promising efficacy against mycobacterial infections. In the context of Mycobacterium tuberculosis, TB47 demonstrates potent bactericidal activity, especially when combined with clofazimine and linezolid, leading to fast sterilization without relapse. Additionally, TB47 exhibits activity against Mycobacterium abscessus, enhancing the effectiveness of clofazimine both in vitro and in vivo. However, TB47 is reported to be ineffective against M. abscessus and does not enhance clofazimine activity. Furthermore, TB47 displays high bactericidal efficacy against Mycobacterium ulcerans, significantly reducing bacterial burden in vivo. Overall, TB47 shows promise as a potential treatment option for mycobacterial infections, particularly when used in combination with other drugs like clofazimine and linezolid.

What are the most common anti-tuberculosis drugs that cause hepatotoxicity?4 answersThe most common anti-tuberculosis drugs that cause hepatotoxicity are isoniazid (INH) and pyrazinamide (PZA). These drugs are commonly used in clinical practice for the treatment of tuberculosis, but long-term medication with INH and PZA can lead to severe liver damage and toxicity. Hepatotoxicity is the most common side effect of anti-tuberculosis drugs, and it can occur within the first few weeks of medication. Monitoring liver function before and after two weeks of starting the anti-TB drug is recommended to detect hepatotoxicity early. Understanding the metabolism of these drugs and the mechanisms behind their hepatotoxicity is important for the early diagnosis and treatment of drug-induced liver injury (DILI).

What are some recent discoveries for tuberculosis?5 answersRecent discoveries in tuberculosis research include the potential of natural products as antitubercular leads. Advances have been made in diagnostic methods, such as identifying latent infections and drug-resistant strains. Genomic research has provided insights into the mycobacterium and may aid in the development of new drugs and vaccines. The history of tuberculosis and its contagious nature have been documented, along with the discovery of Mycobacterium tuberculosis and the development of the first active drug against TB. New methods based on PCR and RFLP have been crucial for diagnosis and epidemiological studies.

Can tuberculosis be treated by antiviral drugs?2 answers

How to cure tuberculosis without medication?6 answers

Which drug is not used now in Alzheimer's disease?6 answers

See what other people are reading

What is Fragile Health System in Conflict Zone?

A fragile health system in a conflict zone refers to a healthcare infrastructure that is severely compromised due to ongoing conflict, leading to challenges in providing essential services and responding to health needs effectively. In conflict-affected regions like Syria, Yemen, Somalia, and South Sudan, health systems face fragmentation, economic losses due to diseases like tuberculosis are exacerbated, and resilience of health systems is tested. These regions experience lower health and development outcomes, hindering progress towards Sustainable Development Goals. The impact of conflict on healthcare workers, facilities, and medical education further complicates the situation, necessitating innovative approaches like the 'hybrid kinetic model' for health professional training in non-government controlled areas. Addressing these challenges requires coordinated efforts to strengthen surveillance, enhance security, and build consensus among stakeholders to mitigate the economic losses and improve healthcare delivery in fragile health systems of conflict zones.What's the clinical application of BMP-2?

The clinical application of Bone Morphogenetic Protein-2 (BMP-2) is extensive, particularly in orthopedics and spine surgery. Research shows that BMP-2 is comparable to or even more effective than autografts in promoting bone coalescence. However, challenges arise due to the high doses required for clinical use, leading to adverse effects and increased costs. BMP-2 plays a crucial role in bone healing, osteogenesis, and bone defect replacement, leading to its FDA approval for spinal fusion surgery, tibial shaft repair, and maxillary sinus reconstructive surgery. Moreover, BMP-2 has shown potential in enhancing radiotherapy sensitivity in colorectal cancer cells, making it a promising therapeutic target for radioresistant cancers. Despite its benefits, caution is advised in certain scenarios, such as avoiding BMP-2 use after limb-salvage surgery in osteosarcoma patients due to potential tumor growth stimulation.Which tuberculosis vaccines failed in clinical trials?

The quest for an effective tuberculosis (TB) vaccine has seen both progress and setbacks, with some candidates failing to meet efficacy expectations in clinical trials. Among these, the MVA85A vaccine, one of the most advanced candidates and the first new TB vaccine candidate to be tested in nearly a century, demonstrated disappointing results. Specifically, a clinical trial revealed that MVA85A had an efficacy rate of less than 20% in protecting children against TB, which was a significant setback given the high hopes pinned on its potential based on earlier trials that showed a good immune response in adults. This outcome was further underscored by another study which reported that MVA85A showed no improved efficacy over the Bacille Calmette-Guérin (BCG) vaccine in preventing TB disease or infection in infants, marking a pivotal moment for TB vaccine development and compelling a re-examination of the immunological approaches underpinning most new TB vaccine efforts. These failures highlight the challenges in developing a vaccine that can effectively prevent TB across different age groups and underscore the complexity of TB immunology. Despite these setbacks, the pursuit of an effective TB vaccine continues, with several candidates in various stages of clinical trials aiming to overcome the limitations of BCG, which, while effective in protecting children against severe forms of TB, has variable efficacy in adults and does not prevent pulmonary TB. The mixed results from these trials emphasize the need for continued research and innovation in TB vaccine development, including exploring novel strategies and understanding protective immunity against TB.What are the key findings and implications of the overall analysis of the FSHR 680 studies on male infertility?

The analysis of FSHR 680 studies on male infertility revealed significant associations between FSHR gene polymorphisms and sperm quality. Studies found that the FSHR rs6166 polymorphism was linked to individual susceptibility to oligoasthenozoospermia in Iraqi men, with a notable decrease in testosterone concentration in affected individuals. Furthermore, investigations into FSHR variants in infertile men undergoing intracytoplasmic sperm injection (ICSI) indicated that these variants could impact sperm concentration, motility, and fertilization rates, emphasizing the importance of genetic factors in male infertility. These findings underscore the relevance of genetic factors, specifically FSHR gene polymorphisms, in influencing male infertility outcomes and highlight the need for further research to confirm and expand upon these results.What is the typical percentage of participants in qualitative research studies?

The typical percentage of participants in qualitative research studies varies based on the method used. In interview studies, the median number of participants is around 30, while focus group studies tend to have slightly more participants, with a median of 36 individuals. Additionally, a study focusing on neurotrophic keratopathy patients found that 14 participants reported various symptoms and impacts, indicating a smaller sample size for qualitative research in this specific medical context. Furthermore, a qualitative content analysis of health science literature revealed that the majority of studies involved single encounters lasting less than 60 minutes, suggesting a limited number of participants in these interactions. Overall, the percentage of participants in qualitative research studies can vary widely depending on the research focus and methodology employed.How do respiratory infections affect the global health system and economies?

Respiratory infections, whether acute or chronic, pose a significant burden on global health systems and economies. These infections, caused by various pathogens including viruses, bacteria, fungi, and parasites, are prevalent in both adults and children. Lower respiratory infections (LRIs) alone contribute to substantial mortality, morbidity, and economic burden worldwide. The burden of LRIs has decreased over time, but they still result in millions of deaths and disability-adjusted life-years (DALYs) annually, with factors like child wasting and household air pollution playing significant roles. Preventative programs focusing on reducing exposure to risk factors are crucial, especially in less developed countries, to alleviate the impact of respiratory infections on global health and economies. Efforts to enhance prevention, control, and treatment strategies for respiratory diseases like COPD, tuberculosis, and pneumonia are essential for improving global health outcomes.What are the number of covid-19 patients in each age groups in the Philippines?

As per the data collected from various studies in the Philippines, the number of COVID-19 patients in different age groups varies. The median age of pediatric COVID-19 cases was 5 years, with children across all age groups being susceptible to the virus. In another study involving patients aged 0 to 18 years, the median age was 10 years, with the majority being adolescents aged 13 to 18 years. Additionally, a study focusing on adult hospitalized patients reported a median age of 52 years. These findings highlight the impact of COVID-19 across different age brackets in the Philippines, emphasizing the importance of tailored interventions and vaccination strategies for various age groups to effectively combat the disease.What are the genes related to pharmaogenetics in tuberuclosis treatment?

Genes related to pharmacogenetics in tuberculosis treatment include NAT2, CYP2E1, CYP2C9, GST, UGT, interleukins, interferon-γ, SLC11A1, and AADAC. These genes play a crucial role in drug metabolism, influencing the efficacy and safety of anti-tuberculosis medications like isoniazid and rifampicin. Variations in these genes can lead to variations in drug concentration, treatment outcomes, susceptibility to tuberculosis, and the risk of adverse reactions such as hepatotoxicity. Studies highlight the importance of identifying genetic polymorphisms to personalize tuberculosis treatment, optimize drug dosing, and minimize adverse effects, ultimately enhancing patient care and treatment outcomes. Pharmacogenomic research aims to revolutionize tuberculosis treatment by tailoring therapies based on individual genetic profiles, potentially improving treatment efficacy and safety.How can gene therapy assist in hereditary blindess?

Gene therapy offers promising solutions for hereditary blindness by targeting inherited retinal diseases (IRDs) caused by mutations in over 250 genes. This approach involves replacing or editing disease-causing genes with functional copies to slow disease progression and potentially restore vision. Gene therapy has shown success in treating IRDs like Leber congenital amaurosis and choroideremia, leading to positive outcomes in patients. By utilizing gene supplementation strategies through subretinal or intravitreal injections, gene therapy aims to address the genetic heterogeneity of IRDs and provide potential clinical benefits to a wide range of patients. With ongoing and planned clinical trials targeting various IRDs such as retinitis pigmentosa, usher syndrome, and Stargardt disease, gene therapy holds significant promise in combating hereditary blindness and improving visual outcomes for affected individuals.What are the potential future research directions in the field of glioblastoma and algae ??

Future research directions in the field of glioblastoma include exploring innovative immunotherapies like immune checkpoint blockade, CAR T cell therapy, oncolytic virotherapy, and vaccine therapy to improve outcomes. Additionally, studies are focusing on combinatorial therapies to enhance antitumor immune responses while minimizing adverse effects, as well as developing techniques to overcome the blood-brain barrier for targeted drug delivery. On the other hand, algae-related research directions were not explicitly mentioned in the provided contexts. However, potential future research directions in algae could involve investigating algae-derived compounds for their therapeutic potential in glioblastoma treatment, exploring algae-based drug delivery systems, or studying the interactions between algae compounds and glioblastoma cells for novel treatment strategies.Do pneumatic compression venous thromboprophylaxis is forbidden with phlebitis ?

Pneumatic compression for venous thromboprophylaxis is not forbidden with phlebitis, but its utility depends on the patient's condition. Mechanical thromboprophylaxis, including pneumatic compression, is recommended in patients at high thrombotic and hemorrhagic risk. In critically ill patients, pneumatic compression can be used in conjunction with pharmacologic thromboprophylaxis to reduce the incidence of deep vein thrombosis. When medical thromboprophylaxis is not feasible, intermittent pneumatic compression devices are widely recommended as an alternative in ICU patients. Additionally, IPCD is suggested for patients in whom pharmacologic thromboprophylaxis is contraindicated. Therefore, while pneumatic compression can be beneficial in certain cases, its use should be carefully considered based on individual patient factors and medical guidelines.